Blanket Purchase Agreement 36F79719D0153-36E79724A0018
Award Date
6/6/24
Last Date to Order
6/5/26
Federal Agency
National Acquisition Center
Awardee
Genzyme Corporation
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the Veterans Integrated Service Network 1 (VISN 1), a division of the Department of Veterans Affairs (VA), to Gojo Industries Inc. The single-award BPA has a ceiling value of $2 and an ultimate completion date of April 14, 2026. The purpose of the BPA is to establish a contract for the MEDICAL SURGICAL PRIME VENDOR (MSPV) program, through which Gojo will provide a wide range of medical and...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA. The BPA was...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...
The Blanket Purchase Agreement (BPA) is an indefinite delivery vehicle (IDV) awarded by a U.S. federal government agency to Supplycore Inc., a prime contractor. The BPA is under the Hardware Superstore Federal Supply Schedule (FSS-51-V), a General Services Administration (GSA) multiple-award schedule contract. The BPA, with a potential value of $9,000,000.00, aims to provide a range of routine consumable and administrative products to support federal government operations. This includes office...
This Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, which is a civilian agency under the U.S. Department of Veterans Affairs (VA). The single-award BPA has a ceiling value of $7,000,000 and was awarded to Aurinia Pharma US Inc., a for-profit pharmaceutical company, to provide the drug Lupkynis. The BPA aims to procure Lupkynis, an immunosuppressant medication recently approved by the FDA for the treatment of...
This Blanket Purchase Agreement (BPA) contract was awarded by the National Acquisition Center, a civilian federal agency, to Merz Pharmaceuticals, LLC, a for-profit foreign-owned organization. The BPA is established under the GSA Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, with a ceiling value of $12,057,300.00 and a period of performance running through March 12, 2026. The purpose of this BPA is to provide the agency with the pharmaceutical products Ampyra and Inbrijia. No...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021. The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Servier Pharmaceuticals LLC as a single-award contract with potential value of $12 million. The BPA is for the purchase of the pharmaceutical products Asparlas and Oncaspar, to be delivered over a base year and four option years. The Department of Veterans Affairs provides healthcare services to military veterans. This BPA aims to procure chemotherapy drugs Asparlas and Oncaspar...